Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Wegovy org - The Untold Story

Employer Coverage for Weight-Loss Drugs Is Tightening for 2027, and the Summary of Benefits Is Where You Will Find Out

Large employers are narrowing GLP-1 weight-loss coverage for 2027. How to read your benefits summary and what to ask HR before open enrollment.

Medical Daily

‘Ozempic face’ and hair loss: what evidence is there for weight-loss drug side-effects?

Research into GLP-1 medications is not always robust but complaints such as digestive problems are well known

The Guardian - UK

Everything you need to know about the new Wegovy pill – and whether you should take it or not

LET’S UNPACK THAT: With massive demand for the GLP-1 tablets as they are approved for use in the UK, Helen Coffey asks experts how they differ from the jab and whether they are the next big step in the weight-loss revolution

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Can Wegovy move the needle on NZ’s obesity crisis, or simply treat its symptoms?

Even before receiving public funding, Wegovy has drawn much media attention in New Zealand for the dramatic difference it can make for weight loss.

The Conversation

Novo Nordisk A/S Q1 Earnings Call Highlights

Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline and regulatory milestones, even as adjusted sales declined because of lower realized prices. Chi

MarketBeat

Early data links Wegovy to risk of 'eye stroke' — here's what to know

A rare form of vision loss has been linked to certain GLP-1s, but more so to Wegovy than to other weight-loss drugs in this class. Should you worry?

LiveScience

Wegovy Tragedy: Woman in Pain with 'Black Tongue' and Lost Organ After Weight Loss Jabs

Sarah-Jayne Crawford's weight-loss journey with Wegovy turned tragic, leading to severe health issues and organ removal. She now warns others about the potential risks of such treatments.

International Business Times UK

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk Just Announced Wegovy Subscriptions. Does That Make NVO Stock a Buy?

Wegovy subscriptions may create interest, but there is a major threat looming for Novo Nordisk.

Barchart

‘Major turning point’ as weight loss drugs to be prescribed to more NHS patients

Wegovy can now be prescribed for weight loss or to help reduce the risk of major cardiovascular events

The Independent UK

Ozempic Controversy Deepens as FDA Accuses Novo Nordisk of Failing to Report Patient Deaths, One Linked To Suicide

Novo Nordisk faces FDA scrutiny for failing to report Ozempic-linked deaths, highlighting systemic issues in safety reporting. Learn about the implications for patient safety and ongoing legal challenges.

International Business Times UK

Weight-loss jab could be made for $3 a month, study finds

Cheap semaglutide, the drug in Ozempic and Wegovy, could help millions with diabetes and obesity in 160 countries

The Guardian - UK

Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is labelled ‘obsolete’

Novo Nordisk’s shares fall sharply after testing of CagriSema falls short of investors’ expectations

The Guardian - UK

Why Denmark can't use Ozempic as a trump card with the US in Greenland talks

Novo Nordisk, the Danish manufacturer of weight-loss drugs Ozempic and Wegovy, has a large market share in the US. But it's not enough to put pressure on US President Donald Trump's administration during Greenland talks, experts say.

Euronews

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

AAP

Weight-loss wonder drugs 'no substitute for exercise'

The weight-loss journey for a growing number of Australians using "miracle" medications must include exercise or risk long-term health problems, experts warn.

Benzinga

Novo Nordisk Q3 2025 Earnings Call Transcript

Novo Nordisk A/S (NASDAQ:NVO) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below. NVO is having a challenging session. See if it is worth your attention here. This transcript is brought to you by Benzinga APIs. For real-time access to our entire…

Benzinga

Discounted Ozempic Could Deflate ETF Optimism Around Hims & Hers

Hims Hers Health Inc (NYSE:HIMS) investors can’t catch a break. Less than two months since Novo Nordisk AS (NYSE:NVO) terminated its Wegovy partnership with the telehealth company abruptly, the pharma giant is again in the news, this time partnering with GoodRx Holdings Inc (NASDAQ:GDRX) to provide discounted access to Ozempic…

Benzinga

Novo Nordisk Freezes Hiring As Wegovy Faces Copycats

Novo Nordisk A/S (NYSE:NVO) has reportedly imposed a global hiring freeze for nonessential roles, as the drugmaker faces rising competition from copycat versions of Wegovy and intensifying rivalry with Eli Lilly and Co (NYSE:LLY).

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

GoodRx Holdings Surges 5% After Hours on Novo Nordisk Partnership for $499 Monthly Ozempic, Wegovy Access

GoodRx Holdings Inc. (NASDAQ:GDRX) shares jumped 5.08% in after-hours trading on Monday, following the announcement of a collaboration with Novo Nordisk A/S (NYSE:NVO) to offer discounted GLP-1 medications at fixed pricing nationwide.

Benzinga

Novo Nordisk Surges On Wegovy Win, Eyes Bullish Rebound Near 52-Week Lows

Novo Nordisk A/S (NYSE:NVO) may have found a timely catalyst. From the lows of its 52-week trading range, the Danish drugmaker is showing signs that a bullish comeback might be on the horizon—driven by both regulatory approval momentum and technically solid market signals.

Benzinga

Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease

On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3…

The Independent UK

‘I lost four stone on Mounjaro – but piled weight back on when I couldn’t afford to keep taking it’

Darren Ratcliffe was paying £270 a month for weight-loss jab Mounjaro

Benzinga

Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio?

These ten large-cap stocks were the worst performers last week. Are they a part of your portfolio?

Benzinga

Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 0.2% on Tuesday.

Evening Standard

Ozempic and Wegovy maker Novo Nordisk sees shares tumble on profit alert

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.